• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of thoraxThoraxInstructions for authorsInstructions for authors
Thorax. Sep 2002; 57(9): 810–816.
PMCID: PMC1746427

A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK

Abstract

Background: This study aimed to describe the clinical, microbiological, molecular epidemiology and treatment of multidrug resistant tuberculosis (MDRTB) cases in the UK and to determine factors associated with survival.

Methods: Ninety MDRTB cases were identified from 1 January 1996 to 30 June 1997; 69 were DNA fingerprinted. Date of diagnosis was determined and data were collated on key demographic factors, clinical, radiological and treatment details. Variables associated with survival were included in a Cox proportional hazards model.

Results: Most of the patients (72.4%) were male, born outside the UK (57.1%), were sputum smear positive (82.2%), and had entered the UK more than 5 years previously (61.9%). Thirty eight of 78 cases (48.7%) had prior TB. Sufficient data on 82 patients were available for survival analysis; 20/27 (74.1%) known to be dead at the end of the observation period had died of tuberculosis. Median survival time overall was 1379 days (95% CI 1336 to 2515) or 3.78 (95% CI 3.66 to 6.89) years (858 days (95% CI 530 to 2515) in immunocompromised individuals (n=32) and 1554 (95% CI 1336 to 2066) days in immunocompetent cases (n=48)). Median survival in patients treated with three drugs to which the bacterium was susceptible on in vitro testing (n=62) was 2066 days (95% CI 1336 to 2515) or 5.66 years, whereas in those not so treated (n=13) survival was 599 days (95% CI 190 to 969) or 1.64 years.

Conclusions: Immunocompromised status, failure to culture the bacterium in 30 days or to apply appropriate three drug treatment, and age were significant factors in mortality. An immunocompromised patient was nearly nine times more likely to die, while application of appropriate treatment reduced the risk (risk ratio 0.06). Increasing age was associated with increasing risk of death (risk ratio 2.079; 95% CI 1.269 to 3.402)—that is, for every 10 year increase in age the risk almost doubled. Overall survival was lower than that reported in previous studies.

Full Text

The Full Text of this article is available as a PDF (108K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet. 1998 Dec 12;352(9144):1886–1891. [PubMed]
  • Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001 Apr 26;344(17):1294–1303. [PubMed]
  • Kumar D, Watson JM, Charlett A, Nicholas S, Darbyshire JH. Tuberculosis in England and Wales in 1993: results of a national survey. Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group. Thorax. 1997 Dec;52(12):1060–1067. [PMC free article] [PubMed]
  • Rose AM, Watson JM, Graham C, Nunn AJ, Drobniewski F, Ormerod LP, Darbyshire JH, Leese J. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax. 2001 Mar;56(3):173–179. [PMC free article] [PubMed]
  • Djuretic T, Herbert J, Drobniewski F, Yates M, Smith EG, Magee JG, Williams R, Flanagan P, Watt B, Rayner A, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax. 2002 Jun;57(6):477–482. [PMC free article] [PubMed]
  • Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR., Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993 Feb 25;328(8):527–532. [PubMed]
  • Fischl MA, Uttamchandani RB, Daikos GL, Poblete RB, Moreno JN, Reyes RR, Boota AM, Thompson LM, Cleary TJ, Lai S. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992 Aug 1;117(3):177–183. [PubMed]
  • Drobniewski F. Is death inevitable with multiresistant TB plus HIV infection? Lancet. 1997 Jan 11;349(9045):71–72. [PubMed]
  • Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med. 1996 Jan;153(1):317–324. [PubMed]
  • Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998 Nov;2(11):877–884. [PubMed]
  • Salomon N, Perlman DC, Friedmann P, Buchstein S, Kreiswirth BN, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis. 1995 Nov;21(5):1245–1252. [PubMed]
  • Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, el-Sadr W, Blum S, Gagliardi A, Salomon N, Turett G. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995 Oct 5;333(14):907–911. [PubMed]
  • Drobniewski FA, Uttley AH. Mycobacterial speciation. Methods Mol Biol. 1998;101:323–347. [PubMed]
  • van Soolingen D, de Haas PE, Hermans PW, Groenen PM, van Embden JD. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol. 1993 Aug;31(8):1987–1995. [PMC free article] [PubMed]
  • Breathnach AS, de Ruiter A, Holdsworth GM, Bateman NT, O'Sullivan DG, Rees PJ, Snashall D, Milburn HJ, Peters BS, Watson J, et al. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect. 1998 Jun;39(2):111–117. [PubMed]
  • Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 1999 Aug;160(2):587–593. [PubMed]
  • Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1998 Jul;53(7):536–548. [PMC free article] [PubMed]
  • Salaniponi FL. The Malawi National Tuberculosis Programme. Bull Int Union Tuberc Lung Dis. 1989 Sep;64(3):40–41. [PubMed]
  • Coninx R, Mathieu C, Debacker M, Mirzoev F, Ismaelov A, de Haller R, Meddings DR. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet. 1999 Mar 20;353(9157):969–973. [PubMed]
  • Drobniewski FA. Diagnosing multidrug resistant tuberculosis in Britain. Clinical suspicion should drive rapid diagnosis. BMJ. 1998 Nov 7;317(7168):1263–1264. [PMC free article] [PubMed]
  • Drobniewski FA, Watterson SA, Wilson SM, Harris GS. A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol. 2000 Mar;49(3):271–278. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...